News Contact Us

U.S. to invest $1.95 billion in Pfizer & BioNTech for COVID-19 vaccine

Author : Pankaj Singh | Published Date : 2020-07-24 

As the COVID-29 pandemic surges on, the Trump administration has reportedly invested nearly $2 billion in a new coronavirus vaccine contract with Pfizer and German pharma company BioNTech to produce mor than 100 million vaccine doses by the end of the year. The U.S. government plans to administer 50 million people through this vaccine if it is effective and safe, as per both companies.

The agreement is for 100 million doses with each vaccine dose costing $20, and designed to be administered in two-dose course. This deal is the highest the U.S. has ever paid for a vaccine, although earlier contracts with other companies were aimed to help pay for vaccine development costs.

However, BioNTech and Pfizer would not get any payments from the U.S. until the vaccine is effective in large clinical studies and also can be successfully produced, a Pfizer spokeswoman stated.

As per the contract terms, the U.S. government would get an option to obtain an additional 500 million doses of the vaccine. Pfizer stated that the price for extra doses would be negotiated only if the government orders them.

While speaking about the vaccine, the U.S. Department of HHS (Health and Human Services) stated that if the vaccine proves to be effective, it would be made available to American citizens at zero cost. However, their health insurance companies might be charged for the vaccine.

Albert Bourla, Chief Executive of Pfizer stated that the company intends to make profits through the vaccine. Spending the company’s own money instead of the government’s money should help to boost the vaccine development process.

Mikael Dolsten, Chief Scientific Officer at Pfizer stated that the company expects to start the vaccine’s late-stage trial in the coming week, pending regulatory authorizations.

Dolsten further added that the company is already starting its procedure of deploying vaccine vials to various clinical sites across the U.S. and elsewhere.

Source credit: https://www.reuters.com/article/us-health-coronavirus-usa-pfizer/u-s-to-pay-pfizer-1-95-billion-to-produce-millions-of-doses-of-covid-19-vaccine-idUSKCN24N1I9  

About Author

Pankaj Singh

Pankaj Singh

Endowed with a post graduate degree in management and finance, Pankaj Singh has been a part of the online content domain for quite a while. Having worked previously as a U.K. insurance underwriter for two years, he now writes articles for fractovia.org and other online portals. He can be contacted at- [email protected] | https://twitter.com/PankajSingh2605

Related News

MAS grants SRFB privileges to StanChart under improved framework

Published Date: 2020-08-03         Author: Pankaj Singh

The Monetary Authority of Singapore (MAS), Singapore’s financial and central bank authority has reportedly awarded SRFB (Significantly Rooted Foreign Bank) privileges to Standard Chartered Singapore, which allows the bank to operate in additional places of business. The agency said in the p... Read More

Grofers records profitable growth, plans IPO listing in late 2021

Published Date: 2020-07-27         Author: Pankaj Singh

The COVID-19 pandemic has managed to stall numerous businesses worldwide. However, online grocery delivery firms have managed to amass considerable revenue growth over the months as a result of stern lockdown norms that have ensued consumers to opt for online food & grocery services. Indian o... Read More

Netflix to test mobile+ cost-efficient subscription plan in India

Published Date: 2020-07-23         Author: Pankaj Singh

The entertainment industry, in the current scenario, has emerged as a highly successful arena in the times of lockdown and social distancing.  With the second-largest population, India's media consumption market has become one of the biggest and fastest-growing in the world.  As such, ... Read More

© 2020 Fractovia. All Rights Reserved